Featured Research

from universities, journals, and other organizations

Whole-brain Radiotherapy After Surgery Or Radiosurgery Not Recommended For Brain Metastases

Date:
September 23, 2009
Source:
ECCO-the European CanCer Organisation
Summary:
Whole-brain radiotherapy should not be given routinely to all patients whose cancer has spread to the brain, according to new research.

Whole-brain radiotherapy should not be given routinely to all patients whose cancer has spread to the brain, say researchers who found that using it after surgery or radiosurgery in patients with a limited number of brain metastases and stable cancer in the rest of the body did not extend lives or help patients remain functionally independent for longer.

In the largest study to date on the issue, scientists reported at Europe's largest cancer congress, ECCO 15 – ESMO 34 [1], in Berlin (Tuesday 22 September) that while the technique did extend the length of time before the cancer got worse and reduced the risk of brain-related deaths, it failed to prolong overall survival or the length of time that patients were able to remain independent in critical functions such as walking, thinking and eating.

Brain metastasis, or spread of cancer to the brain, occurs in 20%-40% of cancer patients and is an important contributor to cancer deaths. Average survival among patients whose tumours have spread to the brain ranges between three months and one year. Treatment options are limited.

Whole-brain radiotherapy is the standard treatment in patients with a single brain metastasis that is not suitable for surgery or radiosurgery, in patients with multiple brain metastases and in those whose cancer is spreading elsewhere in the body.

"However, its use to prevent recurrence after conventional surgery or radiosurgery in patients with a limited number of brain metastases and stable cancer in the rest of the body is controversial. It can slow the spread of cancer in the brain but can damage cognitive functions, sometimes leading to dementia, in long surviving patients," said the leader of the international study, Dr Riccardo Soffietti, Professor of Neuro-Oncology at the University of Torino Medical School in Italy.

"Attitudes toward whole-brain radiotherapy are quite variable across cancer centres at the moment, but, overall, the tendency is to use it in cancers that respond well to radiotherapy, such as breast and lung cancer, and to avoid it in cancers that don't respond well to radiotherapy, such as melanoma, kidney and colon cancer," he said. "The benefits of this treatment have not been fully clarified and because the toxicity could be significant, we need to ensure that there are meaningful advantages to it before it can be widely adopted for this type of patient."

The phase III randomised trial involved 353 patients whose primary tumours were not growing but had spread to the brain, spawning a limited number of brain tumours, or metastases. They all got either surgery to cut the cancer out of the brain, or radiosurgery, a type of targeted radiotherapy performed instead of conventional surgery when it is either too dangerous to remove the tumour or the tumour is small enough to avoid surgery. Half got whole-brain radiotherapy after that, while the rest did not.

There was no statistically significant difference in the length of time that patients were able to function independently, with functionally independent survival lasting 9.5 months in the treatment group and 10 months in the group that got no whole-brain radiotherapy.

Similarly, there was no statistically significant difference in overall survival, with patients getting whole-brain radiotherapy living on average 10.7 months and those not getting it living an average of 10.9 months.

However, the treatment did carry a lower chance of cancer spreading within the brain. Within two years, it had progressed in 54.2% of the patients getting no whole-brain radiotherapy, but only in 31.2% of those getting the treatment. Brain tumour progression killed 25% of the patients in the whole-brain radiotherapy group, compared with 43% in the other group.

Moreover, the study found that the treatment slowed progression of cancer by five weeks, with the treatment group lasting 4.6 months before the disease got worse and the others lasting 3.4 months.

"Although this treatment gives a modest advantage in progression-free survival, it cannot be considered as the standard treatment after surgery or radiosurgery for all patients with brain metastases because it does not prolong the period of functional independence or extend overall survival, which are the key outcomes," Dr Soffietti said. "We are still analysing whether or not the treatment improved quality of life in this study, but we also now need new studies to determine whether it could help some subgroups of patients, such as for instance those with breast cancer."

In the meantime, Dr Soffietti said, doctors must also take into account the fact that recent studies indicate that alternatives may be possible, such as localised radiation after the brain tumour has been cut out or new radiation techniques that spare the areas of the brain involved in cognitive functions that could be damaged by whole-brain radiotherapy.

The study was funded by the European Organisation for Research and Treatment of Cancer.


Story Source:

The above story is based on materials provided by ECCO-the European CanCer Organisation. Note: Materials may be edited for content and length.


Cite This Page:

ECCO-the European CanCer Organisation. "Whole-brain Radiotherapy After Surgery Or Radiosurgery Not Recommended For Brain Metastases." ScienceDaily. ScienceDaily, 23 September 2009. <www.sciencedaily.com/releases/2009/09/090921182709.htm>.
ECCO-the European CanCer Organisation. (2009, September 23). Whole-brain Radiotherapy After Surgery Or Radiosurgery Not Recommended For Brain Metastases. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2009/09/090921182709.htm
ECCO-the European CanCer Organisation. "Whole-brain Radiotherapy After Surgery Or Radiosurgery Not Recommended For Brain Metastases." ScienceDaily. www.sciencedaily.com/releases/2009/09/090921182709.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Stone Fruit Listeria Scare Causes Sweeping Recall

Stone Fruit Listeria Scare Causes Sweeping Recall

Newsy (July 22, 2014) The Wawona Packing Company has issued a voluntary recall on the stone fruit it distributes due to a possible Listeria outbreak. Video provided by Newsy
Powered by NewsLook.com
Huge Schizophrenia Study Finds Dozens Of New Genetic Causes

Huge Schizophrenia Study Finds Dozens Of New Genetic Causes

Newsy (July 22, 2014) The 83 new genetic markers could open dozens of new avenues for schizophrenia treatment research. Video provided by Newsy
Powered by NewsLook.com
CDC Head Concerned About a Post-Antibiotic Era

CDC Head Concerned About a Post-Antibiotic Era

AP (July 22, 2014) Sounding alarms about the growing threat of antibiotic resistance, CDC Director Tom Frieden warned Tuesday if the global community does not confront the problem soon, the world will be living in a devastating post-antibiotic era. (July 22) Video provided by AP
Powered by NewsLook.com
Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins